Soleno Therapeutics, Inc. (SLNO)
NASDAQ: SLNO · Real-Time Price · USD
44.58
-0.61 (-1.34%)
Dec 23, 2024, 2:14 PM EST - Market open
Company Description
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.
The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017.
Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Soleno Therapeutics, Inc.
| Country | United States |
| Founded | 1999 |
| IPO Date | Nov 13, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Anish Bhatnagar |
Contact Details
Address: 203 Redwood Shores Parkway, Suite 500 Redwood City, California 94065 United States | |
| Phone | 650 213 8444 |
| Website | soleno.life |
Stock Details
| Ticker Symbol | SLNO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001484565 |
| CUSIP Number | 834203200 |
| ISIN Number | US8342033094 |
| Employer ID | 77-0523891 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Dr. Anish Bhatnagar M.D. | President, Chief Executive Officer, Chief Operating Officer and Director |
| James H. MacKaness | Chief Financial Officer |
| Patricia C. Hirano M.P.H. | Senior Vice President of Regulatory Affairs |
| Jesse Schumaker | General Counsel |
| Lauren Budesheim | Vice President of People |
| Kristen Yen M.S. | Senior Vice President of Clinical Operations |
| Dr. Neil M. Cowen M.B.A., Ph.D. | Senior Vice President of Drug Development |
| Meredith Manning M.B.A. | Chief Commercial Officer |
| Dr. Michael Huang M.D. | Senior Vice President of Clinical Development |
| Dr. Raymond W. Urbanski M.D., Ph.D. | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 17, 2024 | 8-K | Current Report |
| Nov 26, 2024 | 8-K | Current Report |
| Nov 19, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 14, 2024 | SCHEDULE 13G/A | Filing |
| Nov 14, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | 8-K | Current Report |
| Nov 6, 2024 | 10-Q | Quarterly Report |